Real-World Effectiveness of Risankizumab in Crohn's Disease: Outcome Data for an IL-23 Inhibitor from the Middle East.

Crohns Colitis 360 · 2025 · PMC12674788 · PMID 41346973

Europe PMC DOI

hedged sentence

0.0920

closest p · 1.8× alpha

0.0920

boldest claim

The sentences

did not reach statistical significanceP = .092so close (0.05 < p ≤ 0.1)

During maintenance, clinical remission was numerically more frequent in the AT-naïve group (88.9%) compared to the AT-exposed group (63.3%), though this difference did not reach statistical significance ( P = .092; Figure 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.